港股異動 | 藥明生物高開3% 股價創4個月新高 與GSK就多款創新TCE雙抗/多抗達成許可協議
格隆匯1月5日丨藥明生物(2269.HK)高開3.32%,報68.4港元,總市值2888億港元,股價創4個月新高。藥明生物今日宣佈與葛蘭素史克(GSK)達成許可協議。根據協議,GSK將獲得一款處於臨牀前階段的雙特異性抗體和其他至多三款處於早期發現階段的TCE抗體的全球獨家研究、開發、生產和商業化權利。藥明生物將獲得4000萬美元首付款和最高達14.6億美元的四款TCE抗體的研究、開發、註冊和商業化里程碑付款。藥明生物也有資格獲得基於淨銷售額的分級銷售提成。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.